American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
Upgrade
American Flag

Exelixis Inc

EXEL Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News

Chart provided by TradingView

EXEL historical prices
Income
Balance Sheet
Cash Flow
Revenue Breakdown
Congress Trading

Recent trades of EXEL by members of U.S. Congress

Politician Type Traded
Ro Khanna House / D Sale $1,001 - $15,000 Jan 10, 2024
Ro Khanna House / D Purchase $1,001 - $15,000 Dec 06, 2022
Ro Khanna House / D Sale $1,001 - $15,000 Jan 08, 2020
Donna E. Shalala House / D Sale $1,001 - $15,000 Jun 04, 2019
Donna E. Shalala House / D Sale $1,001 - $15,000 Apr 16, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Feb 06, 2019
Donna E. Shalala House / D Purchase $1,001 - $15,000 Jan 09, 2019
Ro Khanna House / D Purchase $1,001 - $15,000 Oct 25, 2018
Ro Khanna House / D Sale $1,001 - $15,000 Jun 15, 2018
Ro Khanna House / D Purchase $1,001 - $15,000 Apr 03, 2018
EXEL Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
EXEL Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
EXEL Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes in EXEL holdings by institutional investors

Insider Trading

Quarterly net insider trading by EXEL's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
View Strategy Copytrade Strategy
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

See Pricing
schema-2
Corporate Lobbying

Government lobbying spending instances

  • $560,000 Jul 20, 2026 Issue: Health Issues Taxation/Internal Revenue Code
  • $520,000 Apr 20, 2026 Issue: Health Issues Taxation/Internal Revenue Code
  • $510,000 Jan 20, 2026 Issue: Health Issues Taxation/Internal Revenue Code
  • $510,000 Jan 20, 2026 Issue: Health Issues Taxation/Internal Revenue Code
  • $480,000 Jul 21, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Apr 18, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Jan 21, 2025 Issue: Health Issues Taxation/Internal Revenue Code
  • $460,000 Oct 21, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 22, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $450,000 Jan 19, 2024 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Oct 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $460,000 Jul 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $330,000 Jan 20, 2023 Issue: Taxation/Internal Revenue Code Health Issues
  • $320,000 Oct 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $300,000 Jul 19, 2022 Issue: Taxation/Internal Revenue Code Health Issues
  • $290,000 Apr 19, 2022 Issue: Health Issues
  • $280,000 Jan 19, 2022 Issue: HEALTH ISSUES
  • $230,000 Oct 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Jul 20, 2021 Issue: HEALTH ISSUES
  • $220,000 Apr 19, 2021 Issue: HEALTH ISSUES
  • $220,000 Jan 20, 2021 Issue: HEALTH ISSUES
  • $240,000 Oct 20, 2020 Issue: HEALTH ISSUES
  • $240,000 Jul 20, 2020 Issue: HEALTH ISSUES
  • $220,000 Apr 20, 2020 Issue: HEALTH ISSUES
  • $190,000 Jan 21, 2020 Issue: HEALTH ISSUES
  • $180,000 Oct 21, 2019 Issue: Health Issues
  • $320,000 Jul 22, 2019 Issue: Health Issues
  • $300,000 Apr 22, 2019 Issue: Health Issues
  • $20,000 Jan 22, 2019 Issue: Medicare/Medicaid Health Issues
  • $60,000 Jan 17, 2019 Issue: Health Issues
  • $60,000 Oct 09, 2018 Issue: Health Issues
  • $60,000 Jul 18, 2018 Issue: Health Issues
  • $50,000 Apr 19, 2018 Issue: Health Issues
Revolving Door

Former government officials who have lobbied for EXEL

31 former government officials from 18 congressional offices at 7 lobbying firms have lobbied for EXEL, most recently Jul 21, 2026.

  • John B. Shadegg
    Paul Edattel House Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg Formerly with John B. Shadegg · TODD STRATEGY GROUP · Jul 21, 2026
  • Daniel Todd Senate Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid Formerly Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Ad · TODD STRATEGY GROUP · Jul 21, 2026
  • Brett Guthrie
    Eric Bergren House Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 21, 2026
  • Brett Guthrie
    Katherine Cotton House Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie Formerly with Brett Guthrie · TODD STRATEGY GROUP · Jul 21, 2026
  • Ron Kind House New Member of Congress, U.S. House of Representatives (1997-2023) Formerly Member of Congress, U.S. House of Representatives (1997-2023) · ARNOLD & PORTER KAYE SCHOLER LLP · Jul 20, 2026
  • J. Dennis Hastert
    Darren Willcox House Asst. for Policy, Speaker Dennis Hastert; Admin. Asst., Legislative Director, Legislative Asst., Cong. Porter Goss; House Rules Comm. Assoc., Subcommittee Staff Director Formerly with J. Dennis Hastert · W STRATEGIES, LLC · Jul 20, 2026
  • Catherine Finley Senate Staff Director, Senate Special Aging Committee; Senior Health Policy Advisor, Sen. Smith; Legislative Asst, Sen. Snowe Formerly Smith · THORN RUN PARTNERS · Jul 20, 2026
  • Thom Tillis
    Ted Lehman Senate Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant Formerly with Thom Tillis · TODD STRATEGY GROUP · Apr 20, 2026
See all 31 on the Revolving Door dashboard
Corporate Lobbying

EXEL Estimated quarterly lobbying spending

Revenue Breakdown

EXEL Revenue by Segment or Geography

By Segment
By Geography
EXEL Income Statement
EXEL Balance Sheet
EXEL Cash Flow
U.S. Patents

New EXEL patent grants

  • Patent Title: Process for preparing quinoline derivatives May. 15, 2018
  • Patent Title: Method of treating cancer Jan. 09, 2018
  • Patent Title: Malate salt of n-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n′(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer Nov. 07, 2017
  • Patent Title: Process for making compounds for use in the treatment of cancer Sep. 26, 2017
  • Patent Title: C-met modulator pharmaceutical compositions Aug. 08, 2017
  • Patent Title: Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds Aug. 01, 2017
  • Patent Title: Inhibitors of pi3k-delta and methods of their use and manufacture Jun. 06, 2017
  • Patent Title: Process for preparing quinoline derivatives Jun. 14, 2016
  • Patent Title: Inhibitors of pi3k-delta and methods of their use and manufacture May. 24, 2016
  • Patent Title: Combinations of kinase inhibitors for the treatment of cancer Apr. 21, 2015
  • Patent Title: Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors Dec. 02, 2014
  • Patent Title: Phosphatidylinositol 3-kinase inhibitors and methods of their use Nov. 18, 2014
  • Patent Title: (l)-malate salt of n-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Nov. 04, 2014
  • Patent Title: Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents Aug. 12, 2014
  • Patent Title: Acetanilide sphingosine-1-phosphate receptor antagonists Jul. 29, 2014
  • Patent Title: Scds as modifiers of the p53 pathway and methods of use Jul. 08, 2014
  • Patent Title: Cdk9 as modifier of the igf pathway and methods of use Jun. 24, 2014
  • Patent Title: Quinazolinone modulators of nuclear receptors Jun. 10, 2014
  • Patent Title: Pyrazole kinase modulators and methods of use Apr. 29, 2014
  • Patent Title: Raf modulators and methods of use Apr. 15, 2014
  • Patent Title: Eef2k as modifiers of the pten/akt pathway and methods of use Mar. 25, 2014
  • Patent Title: Crystalline forms on n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mar. 18, 2014
  • Patent Title: Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture Feb. 11, 2014
  • Patent Title: 1-phenylpyrrole derivatives Feb. 04, 2014
  • Patent Title: Method of using pi3k and mek modulators Feb. 04, 2014
  • Patent Title: Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture Jan. 28, 2014
  • Patent Title: Plks as modifiers of the beta catenin pathway and methods of use Jan. 21, 2014
  • Patent Title: Azepinoindole derivatives as pharmaceutical agents Sep. 03, 2013
  • Patent Title: Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha Aug. 20, 2013
  • Patent Title: C-met modulators and method of use Jul. 30, 2013
  • Patent Title: Atropisomers of (hydroxyalkyl) pyrrole derivatives Jul. 16, 2013
  • Patent Title: Pik4ca as modifier of the rac pathway and methods of use Jul. 09, 2013
  • Patent Title: Combination therapies comprising quinoxaline inhibitors of p13k-alpha for use in the treatment of cancer Jul. 09, 2013
  • Patent Title: C-met modulators and method of use Jul. 02, 2013
  • Patent Title: Azepine derivatives as pharmaceutical agents Jun. 18, 2013
  • Patent Title: Substituted pyrimidine compositions and methods of use Jun. 04, 2013
  • Patent Title: 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use May. 14, 2013
  • Patent Title: Rors as modifiers of the p21 pathway and methods of use Apr. 23, 2013
  • Patent Title: Pyrazolo pyrimidines as casein kinase ii (ck2) modulators Feb. 12, 2013
  • Patent Title: Pyrrole derivatives as pharmaceutical agents Feb. 05, 2013
  • Patent Title: C-kit modulators and methods of use Jan. 29, 2013
  • Patent Title: Azetidines as mek inhibitors for the treatment of proliferative diseases Jan. 29, 2013
  • Patent Title: Pyrimidinones as casein kinase ii (ck2) modulators Dec. 04, 2012
  • Patent Title: Pgds as modifiers of the pten pathway and methods of use Oct. 16, 2012
  • Patent Title: Marks as modifers of the pten pathway and methods of use Sep. 25, 2012
  • Patent Title: Map3ks as modifiers of the p53 pathway and methods of use Sep. 18, 2012
  • Patent Title: Pyridopyrimidinone inhibitors of pi3kα for the treatment of cancer Aug. 21, 2012
  • Patent Title: 6-phenylpyrimidinones as pim modulators Aug. 14, 2012
  • Patent Title: Methods of using igfir and abl kinase modulators Jul. 17, 2012
  • Patent Title: Pyrimidine derivatives as kinase modulators and method of use Jul. 03, 2012
Government Contracts

Federal grants, loans, and purchases

Government Contracts

Estimated quarterly amount awarded to EXEL from public contracts

EXEL News

Recent insights relating to EXEL

CNBC Recommendations

Recent picks made for EXEL stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in EXEL

EXEL Analyst Ratings

EXEL Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
EXEL Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $EXEL stock a Buy, Sell, or Hold?

  • What is the price target for $EXEL stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

EXEL Top Shareholders
Shareholder
Shares Held
EXEL Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $EXEL stock?

  • Who owns the most shares of $EXEL stock?

  • What funds own $EXEL stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

EXEL Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view EXEL Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About EXEL

Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

  • Address Alameda, CA
  • Market Cap 14.1 billion
  • Employees 1,077
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Exelixis Inc (EXEL) Historical Stock Prices

Exelixis Inc (EXEL) closed at $56.73 on September 23, 2026. Over the past year its adjusted close ranged from $34.54 to $59.13. Daily prices go back to January 2, 2014, 3,200 trading days in all.

  • 1 month+4.00%
  • 3 months+7.30%
  • Year to date+29.43%
  • 1 year+42.50%
  • 3 years+164.11%
  • 5 years+178.77%
  • Max+817.96%
See every congressional and insider trade on the EXEL price chart

Quiver Premium charts EXEL's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 58.22 58.66 56.26 56.73 56.73 1,431,534
Sep 22, 2026 57.65 59.09 57.33 58.15 58.15 1,860,283
Sep 21, 2026 58.61 58.80 56.90 57.22 57.22 2,102,596
Sep 18, 2026 58.28 59.15 57.90 58.36 58.36 5,243,436
Sep 17, 2026 57.23 58.52 57.23 58.49 58.49 1,785,586
Sep 16, 2026 57.04 57.78 56.33 56.78 56.78 1,879,641
Sep 15, 2026 55.93 56.97 54.95 56.90 56.90 1,980,448
Sep 14, 2026 56.44 57.07 55.91 56.21 56.21 1,739,463
Sep 11, 2026 56.76 57.43 54.55 56.12 56.12 2,916,863
Sep 10, 2026 58.33 58.33 57.23 57.43 57.43 1,789,572
Sep 9, 2026 57.60 58.36 56.95 58.33 58.33 1,770,279
Sep 8, 2026 58.97 59.41 57.55 57.67 57.67 2,538,923
Sep 4, 2026 58.50 59.26 58.45 59.01 59.01 1,580,988
Sep 3, 2026 58.75 59.72 58.20 59.13 59.13 2,141,585
Sep 2, 2026 57.21 59.11 56.70 58.53 58.53 2,851,454
Sep 1, 2026 54.75 56.97 54.75 56.89 56.89 2,413,531
Aug 31, 2026 54.10 55.02 53.43 54.64 54.64 2,246,348
Aug 28, 2026 55.14 55.25 54.12 54.45 54.45 1,486,617
Aug 27, 2026 55.76 56.08 54.83 55.26 55.26 1,489,697
Aug 26, 2026 56.54 56.90 56.06 56.10 56.10 1,816,723
Aug 25, 2026 54.95 56.74 54.95 56.72 56.72 2,024,358
Aug 24, 2026 53.89 54.79 53.39 54.55 54.55 2,423,091
Aug 21, 2026 53.74 54.68 53.70 54.08 54.08 1,949,764
Aug 20, 2026 53.76 54.50 53.44 53.69 53.69 1,950,664
Aug 19, 2026 53.46 54.58 53.10 54.39 54.39 2,503,640
Aug 18, 2026 52.32 53.36 52.11 53.12 53.12 1,290,526
Aug 17, 2026 51.25 52.70 50.80 52.32 52.32 2,372,576
Aug 14, 2026 50.32 51.29 50.02 51.24 51.24 2,342,519
Aug 13, 2026 50.54 51.14 49.97 50.61 50.61 1,948,740
Aug 12, 2026 51.00 51.52 50.30 50.38 50.38 2,938,705
Aug 11, 2026 52.87 53.49 51.14 51.33 51.33 2,038,685
Aug 10, 2026 54.00 54.02 52.47 52.96 52.96 3,349,673
Aug 7, 2026 52.69 54.14 52.17 54.07 54.07 3,550,012
Aug 6, 2026 52.92 55.44 51.76 52.20 52.20 5,410,948
Aug 5, 2026 56.27 56.95 55.57 56.70 56.70 4,202,047
Aug 4, 2026 55.06 56.47 54.26 56.00 56.00 2,729,948
Aug 3, 2026 53.06 55.15 52.32 55.06 55.06 4,301,629
Jul 31, 2026 55.76 56.18 52.79 53.03 53.03 3,025,578
Jul 30, 2026 54.90 56.11 54.61 55.97 55.97 2,486,679
Jul 29, 2026 56.45 56.59 55.14 55.33 55.33 1,882,518
Jul 28, 2026 56.40 56.85 55.33 56.51 56.51 2,489,469
Jul 27, 2026 55.81 56.73 55.69 55.81 55.81 2,316,906
Jul 24, 2026 56.07 56.34 55.11 55.37 55.37 1,838,009
Jul 23, 2026 54.58 55.71 54.20 55.65 55.65 1,659,664
Jul 22, 2026 56.00 56.06 54.93 54.98 54.98 1,656,466
Jul 21, 2026 55.66 56.44 55.05 56.12 56.12 1,820,120
Jul 20, 2026 56.11 56.69 55.50 55.53 55.53 2,381,658
Jul 17, 2026 55.00 56.10 54.75 55.92 55.92 2,555,561
Jul 16, 2026 55.55 56.75 55.29 55.68 55.68 2,031,019
Jul 15, 2026 55.32 55.92 54.39 55.55 55.55 1,895,909
Jul 14, 2026 55.75 56.03 55.10 55.77 55.77 1,799,548
Jul 13, 2026 56.24 56.47 55.08 56.04 56.04 2,844,304
Jul 10, 2026 57.19 57.27 55.66 56.50 56.50 3,219,800
Jul 9, 2026 56.02 57.42 56.02 57.10 57.10 2,511,853
Jul 8, 2026 56.57 56.87 55.37 56.11 56.11 1,783,224
Jul 7, 2026 56.16 57.57 55.80 57.08 57.08 3,334,609
Jul 6, 2026 55.91 55.97 54.85 55.53 55.53 3,143,396
Jul 2, 2026 54.43 56.21 54.10 55.85 55.85 2,364,108
Jul 1, 2026 54.20 54.47 53.25 53.96 53.96 1,843,248
Jun 30, 2026 54.63 54.88 54.00 54.41 54.41 2,599,397
Jun 29, 2026 55.00 55.91 53.91 54.28 54.28 2,587,750
Jun 26, 2026 53.45 55.15 53.08 54.77 54.77 6,931,468
Jun 25, 2026 52.72 53.70 51.77 53.23 53.23 2,256,253
Jun 24, 2026 51.88 53.09 51.70 52.87 52.87 2,931,626
Jun 23, 2026 51.39 52.06 50.88 51.34 51.34 2,574,378
Jun 22, 2026 52.00 52.95 50.80 51.35 51.35 3,504,387
Jun 18, 2026 53.07 53.12 50.96 51.91 51.91 6,545,171
Jun 17, 2026 52.10 53.00 51.55 52.44 52.44 2,016,149
Jun 16, 2026 53.34 53.35 52.07 52.10 52.10 1,676,459
Jun 15, 2026 53.30 53.35 52.03 53.00 53.00 2,025,466
Jun 12, 2026 53.50 53.87 53.05 53.13 53.13 1,584,587
Jun 11, 2026 52.66 53.93 52.49 53.50 53.50 1,823,879
Jun 10, 2026 52.74 53.82 52.53 52.58 52.58 3,104,622
Jun 9, 2026 52.52 53.28 52.01 52.99 52.99 1,774,751
Jun 8, 2026 52.74 52.89 51.32 51.74 51.74 1,918,462
Jun 5, 2026 52.44 52.98 52.20 52.70 52.70 2,161,997
Jun 4, 2026 51.97 52.79 51.46 52.49 52.49 2,409,781
Jun 3, 2026 48.62 51.63 48.10 51.60 51.60 2,979,299
Jun 2, 2026 50.28 50.44 48.40 48.54 48.54 3,037,202
Jun 1, 2026 50.87 50.94 49.70 50.28 50.28 2,447,429
May 29, 2026 51.41 51.72 50.42 50.48 50.48 2,951,593
May 28, 2026 50.04 52.96 50.00 51.45 51.45 3,572,255
May 27, 2026 50.37 50.89 49.86 50.03 50.03 2,434,866
May 26, 2026 50.55 50.71 49.51 49.98 49.98 2,104,267
May 22, 2026 49.75 50.33 49.51 50.15 50.15 1,543,918
May 21, 2026 49.43 50.00 49.01 49.65 49.65 1,487,989
May 20, 2026 49.00 50.20 48.88 49.90 49.90 2,414,604
May 19, 2026 49.47 49.70 48.21 48.67 48.67 2,843,822
May 18, 2026 50.32 50.53 49.44 49.84 49.84 2,596,104
May 15, 2026 51.09 51.30 49.59 50.13 50.13 2,069,205
May 14, 2026 51.49 51.63 50.27 51.10 51.10 2,420,763
May 13, 2026 49.82 51.48 49.62 51.29 51.29 3,241,148
May 12, 2026 50.00 50.00 48.82 49.46 49.46 2,766,765
May 11, 2026 48.26 50.48 48.20 49.71 49.71 3,831,186
May 8, 2026 46.59 48.17 46.46 48.16 48.16 2,179,091
May 7, 2026 48.45 48.70 45.65 46.21 46.21 3,519,429
May 6, 2026 47.68 48.92 45.21 48.70 48.70 6,340,220
May 5, 2026 44.45 45.21 44.13 44.42 44.42 3,563,501
May 4, 2026 43.51 44.32 43.50 44.17 44.17 3,144,925
May 1, 2026 44.00 44.30 43.50 43.68 43.68 3,955,281
Apr 30, 2026 45.06 45.41 44.23 44.46 44.46 2,153,269
Apr 29, 2026 44.58 45.19 44.10 44.69 44.69 1,857,471
Apr 28, 2026 44.72 45.54 44.72 44.93 44.93 1,984,935
Apr 27, 2026 44.89 45.82 44.61 44.65 44.65 2,103,801
Apr 24, 2026 46.29 46.65 44.54 44.94 44.94 2,342,964
Apr 23, 2026 46.70 47.27 45.68 46.05 46.05 2,418,074
Apr 22, 2026 46.33 47.47 45.72 46.85 46.85 3,533,587
Apr 21, 2026 44.18 46.00 44.12 45.89 45.89 3,498,103
Apr 20, 2026 44.99 45.25 43.53 43.61 43.61 2,045,500
Apr 17, 2026 45.00 45.43 44.62 44.89 44.89 2,496,161
Apr 16, 2026 44.13 44.69 43.97 44.38 44.38 2,069,847
Apr 15, 2026 45.95 46.10 44.00 44.28 44.28 2,187,909
Apr 14, 2026 45.15 46.03 45.01 45.86 45.86 2,533,407
Apr 13, 2026 44.09 45.00 43.75 44.96 44.96 2,224,775
Apr 10, 2026 45.45 45.45 43.91 44.27 44.27 2,945,426
Apr 9, 2026 44.00 45.56 43.82 45.41 45.41 1,813,072
Apr 8, 2026 44.60 44.72 43.92 44.20 44.20 2,629,277
Apr 7, 2026 43.95 44.45 43.75 43.99 43.99 2,386,716
Apr 6, 2026 43.65 44.16 43.55 43.98 43.98 1,723,204
Apr 2, 2026 43.74 43.91 43.32 43.88 43.88 1,664,733
Apr 1, 2026 43.04 44.19 42.50 44.04 44.04 1,872,071
Mar 31, 2026 42.61 43.16 42.42 42.89 42.89 1,926,966
Mar 30, 2026 41.82 42.24 41.57 41.95 41.95 2,103,865
Mar 27, 2026 42.36 42.70 41.49 41.53 41.53 1,762,621
Mar 26, 2026 42.61 43.20 42.33 42.36 42.36 1,703,349
Mar 25, 2026 42.00 43.48 41.87 42.78 42.78 1,832,270
Mar 24, 2026 41.16 41.86 40.84 41.57 41.57 2,540,030
Mar 23, 2026 41.80 42.20 41.39 41.41 41.41 2,614,120
Mar 20, 2026 41.10 41.72 40.90 41.27 41.27 6,698,464
Mar 19, 2026 40.94 41.62 40.90 41.26 41.26 2,095,346
Mar 18, 2026 41.52 41.88 41.02 41.26 41.26 2,220,800
Mar 17, 2026 41.36 42.13 41.24 41.83 41.83 2,379,435
Mar 16, 2026 41.60 41.63 40.97 41.07 41.07 2,258,906
Mar 13, 2026 41.66 41.74 40.55 41.24 41.24 2,235,713
Mar 12, 2026 41.57 41.57 40.52 41.17 41.17 2,785,208
Mar 11, 2026 41.17 41.83 41.07 41.75 41.75 2,280,589
Mar 10, 2026 42.50 42.66 41.16 41.29 41.29 4,073,360
Mar 9, 2026 41.01 42.47 40.68 42.37 42.37 3,167,107
Mar 6, 2026 40.54 41.62 40.24 41.55 41.55 2,713,250
Mar 5, 2026 41.25 41.35 40.48 41.28 41.28 3,438,778
Mar 4, 2026 41.06 41.83 40.69 41.69 41.69 4,254,229
Mar 3, 2026 40.55 41.20 40.20 40.74 40.74 3,472,103
Mar 2, 2026 42.00 43.25 39.71 41.03 41.03 7,825,813
Feb 27, 2026 43.96 44.88 43.51 44.06 44.06 4,840,200
Feb 26, 2026 44.91 45.01 44.12 44.28 44.28 2,714,013
Feb 25, 2026 45.60 45.87 44.74 44.75 44.75 2,255,438
Feb 24, 2026 43.91 45.27 43.53 45.14 45.14 2,877,956
Feb 23, 2026 43.50 44.49 43.45 44.01 44.01 2,362,405
Feb 20, 2026 44.03 44.29 43.45 43.63 43.63 1,959,230
Feb 19, 2026 44.15 44.65 43.75 44.16 44.16 2,766,159
Feb 18, 2026 44.00 44.64 43.20 44.47 44.47 3,268,049
Feb 17, 2026 43.96 44.67 43.50 44.08 44.08 2,977,786
Feb 13, 2026 42.89 44.05 42.73 43.92 43.92 2,055,214
Feb 12, 2026 42.83 43.52 42.35 42.70 42.70 2,556,519
Feb 11, 2026 43.46 43.83 40.92 42.94 42.94 3,954,289
Feb 10, 2026 43.97 44.28 42.93 42.98 42.98 3,252,470
Feb 9, 2026 43.94 44.15 43.45 43.95 43.95 2,184,561
Feb 6, 2026 42.86 44.20 42.75 43.90 43.90 3,364,665
Feb 5, 2026 42.70 43.70 42.17 42.37 42.37 2,381,532
Feb 4, 2026 42.79 43.41 42.22 42.65 42.65 2,608,857
Feb 3, 2026 42.51 43.54 42.28 42.59 42.59 2,393,866
Feb 2, 2026 42.01 42.83 40.54 42.81 42.81 4,146,633
Jan 30, 2026 42.18 42.50 40.76 41.36 41.36 3,436,238
Jan 29, 2026 42.63 43.29 41.90 42.28 42.28 3,116,307
Jan 28, 2026 43.52 43.61 42.32 42.66 42.66 2,330,455
Jan 27, 2026 43.80 44.85 43.23 43.74 43.74 1,925,104
Jan 26, 2026 44.47 44.98 43.53 43.61 43.61 2,263,635
Jan 23, 2026 44.64 45.37 44.12 44.27 44.27 2,117,508
Jan 22, 2026 45.00 45.04 44.10 44.50 44.50 2,202,271
Jan 21, 2026 43.72 45.41 43.70 44.81 44.81 2,007,910
Jan 20, 2026 43.14 44.28 43.00 43.78 43.78 1,662,807
Jan 16, 2026 45.44 45.52 43.54 43.96 43.96 2,898,708
Jan 15, 2026 45.52 45.77 45.14 45.44 45.44 2,268,764
Jan 14, 2026 44.28 45.34 44.02 45.23 45.23 1,722,698
Jan 13, 2026 44.06 45.05 43.73 44.08 44.08 2,082,466
Jan 12, 2026 42.59 45.06 42.05 44.06 44.06 4,143,134
Jan 9, 2026 44.28 45.42 43.88 44.04 44.04 2,830,916
Jan 8, 2026 45.37 45.84 43.28 44.15 44.15 2,728,794
Jan 7, 2026 44.25 46.31 44.03 46.19 46.19 2,543,909
Jan 6, 2026 42.17 43.93 42.17 43.68 43.68 2,381,784
Jan 5, 2026 42.91 43.46 41.93 42.40 42.40 2,916,780
Jan 2, 2026 43.52 43.73 43.00 43.58 43.58 2,489,480
Dec 31, 2025 43.94 44.22 43.50 43.83 43.83 1,757,099
Dec 30, 2025 45.19 45.41 44.02 44.04 44.04 1,814,234
Dec 29, 2025 45.95 46.29 45.30 45.37 45.37 1,825,287
Dec 26, 2025 46.56 46.94 45.96 46.24 46.24 1,537,799
Dec 24, 2025 46.80 47.00 46.32 46.51 46.51 1,079,632
Dec 23, 2025 46.76 47.24 45.95 46.61 46.61 3,055,567
Dec 22, 2025 44.25 46.24 44.10 46.19 46.19 3,017,805
Dec 19, 2025 42.76 44.55 42.67 44.30 44.30 5,242,441
Dec 18, 2025 41.96 43.11 41.94 42.57 42.57 2,220,388
Dec 17, 2025 41.66 42.03 41.55 42.00 42.00 2,117,143
Dec 16, 2025 41.13 41.77 40.83 41.60 41.60 2,213,013
Dec 15, 2025 41.41 42.09 41.19 41.38 41.38 3,070,235
Dec 12, 2025 41.66 41.79 40.66 40.88 40.88 2,569,223
Dec 11, 2025 41.28 41.79 40.81 41.39 41.39 2,794,345
Dec 10, 2025 42.05 42.36 41.03 41.07 41.07 3,239,688
Dec 9, 2025 42.17 42.73 41.52 41.87 41.87 2,890,361
Dec 8, 2025 44.50 44.59 41.88 42.17 42.17 3,667,225
Dec 5, 2025 44.20 44.59 43.85 44.36 44.36 2,193,734
Dec 4, 2025 43.97 44.79 43.95 44.37 44.37 2,055,158
Dec 3, 2025 43.57 44.48 43.47 44.01 44.01 2,729,381
Dec 2, 2025 43.77 43.98 43.00 43.44 43.44 2,244,956
Dec 1, 2025 43.84 44.11 43.33 43.43 43.43 2,477,601
Nov 28, 2025 44.91 44.91 44.09 44.17 44.17 1,528,537
Nov 26, 2025 43.03 44.44 42.96 44.21 44.21 2,086,428
Nov 25, 2025 42.50 43.59 42.25 43.13 43.13 2,885,593
Nov 24, 2025 42.31 43.00 42.15 42.25 42.25 4,519,047
Nov 21, 2025 42.08 42.86 41.82 42.51 42.51 2,811,344
Nov 20, 2025 42.32 42.50 41.69 41.78 41.78 2,318,621
Nov 19, 2025 42.95 42.99 41.65 42.14 42.14 2,195,362
Nov 18, 2025 41.76 42.73 41.76 42.65 42.65 2,036,289
Nov 17, 2025 41.58 43.16 41.58 42.42 42.42 2,336,473
Nov 14, 2025 41.93 42.59 41.23 41.65 41.65 2,571,943
Nov 13, 2025 43.09 43.72 42.18 42.35 42.35 3,087,254
Nov 12, 2025 42.98 43.68 42.62 43.59 43.59 2,440,423
Nov 11, 2025 41.45 43.22 41.45 42.98 42.98 2,860,572
Nov 10, 2025 41.03 41.54 39.83 41.41 41.41 2,627,033
Nov 7, 2025 40.63 40.83 39.93 40.81 40.81 2,321,902
Nov 6, 2025 40.05 41.21 40.05 40.80 40.80 2,936,557
Nov 5, 2025 40.00 41.55 38.19 40.37 40.37 4,959,797
Nov 4, 2025 37.81 38.90 37.58 37.90 37.90 3,474,902
Nov 3, 2025 37.55 38.41 36.00 38.06 38.06 4,529,011
Oct 31, 2025 38.62 38.96 38.25 38.67 38.67 2,112,391
Oct 30, 2025 39.48 39.76 38.92 38.94 38.94 2,209,899
Oct 29, 2025 40.01 40.24 39.38 39.43 39.43 1,892,481
Oct 28, 2025 40.01 40.62 39.45 40.08 40.08 2,012,002
Oct 27, 2025 39.04 40.02 38.91 39.99 39.99 2,268,154
Oct 24, 2025 38.00 39.15 37.82 38.72 38.72 2,429,262
Oct 23, 2025 36.27 38.33 36.08 38.05 38.05 3,861,093
Oct 22, 2025 36.02 36.45 35.44 36.08 36.08 3,102,619
Oct 21, 2025 35.05 36.13 34.63 36.13 36.13 5,647,095
Oct 20, 2025 35.55 36.17 33.76 34.54 34.54 9,439,327
Oct 17, 2025 39.33 39.59 38.62 39.25 39.25 2,188,516
Oct 16, 2025 39.99 40.05 39.06 39.21 39.21 1,907,487
Oct 15, 2025 39.53 40.54 39.46 40.03 40.03 1,887,599
Oct 14, 2025 38.46 39.90 38.18 39.51 39.51 3,135,220
Oct 13, 2025 38.36 38.79 37.52 38.44 38.44 2,227,094
Oct 10, 2025 38.67 38.71 37.71 38.15 38.15 2,933,242
Oct 9, 2025 38.91 39.09 38.27 38.57 38.57 1,680,561
Oct 8, 2025 39.42 39.48 38.59 38.64 38.64 3,129,379
Oct 7, 2025 40.15 40.20 38.98 39.63 39.63 2,064,144
Oct 6, 2025 40.29 40.43 39.68 40.01 40.01 1,905,651
Oct 3, 2025 41.44 41.45 40.05 40.09 40.09 2,211,802
Oct 2, 2025 41.23 41.40 40.44 41.35 41.35 1,876,512
Oct 1, 2025 41.30 41.78 40.86 41.20 41.20 2,528,836
Sep 30, 2025 40.47 41.60 40.35 41.30 41.30 2,171,413
Sep 29, 2025 39.17 40.60 39.00 40.57 40.57 2,533,580
Sep 26, 2025 38.73 39.24 38.57 39.04 39.04 1,638,603
Sep 25, 2025 38.83 38.91 38.35 38.69 38.69 1,770,572
Sep 24, 2025 39.70 39.99 38.56 38.91 38.91 2,014,263
Sep 23, 2025 39.59 39.96 39.47 39.81 39.81 1,460,301

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Exelixis Inc Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at EXEL, per a recent SEC DEF 14A filing. We estimate that the median employee at EXELIXIS, INC. is paid $319,050.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation